The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder
Castagna P, Farahdel E, Potenza M, Crowley M. The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder. Expert Opinion On Pharmacotherapy 2023, 24: 835-847. PMID: 37074259, PMCID: PMC10197951, DOI: 10.1080/14656566.2023.2199921.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdolescentAnxiety DisordersChildHumansSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsConceptsSelective serotonin reuptake inhibitorsSelective norepinephrine reuptake inhibitorGeneralized anxiety disorderAnxiety disordersReuptake inhibitorsPediatric generalized anxiety disorderBetter long-term outcomesSecond-line treatmentNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsFirst-line interventionLong-term outcomesCombination of psychotherapyPrevalent psychiatric disordersEvidence-based statePediatric anxiety disordersArt pharmacotherapyModerate effect sizeFunctional outcomeEarly recognitionMood disordersElevated riskPsychiatric disordersBetter outcomesElectronic databases